0000899243-20-000660.txt : 20200106 0000899243-20-000660.hdr.sgml : 20200106 20200106213020 ACCESSION NUMBER: 0000899243-20-000660 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200102 FILED AS OF DATE: 20200106 DATE AS OF CHANGE: 20200106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HENDERSON MICHAEL THOMAS CENTRAL INDEX KEY: 0001779990 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38959 FILM NUMBER: 20511989 MAIL ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BridgeBio Pharma, Inc. CENTRAL INDEX KEY: 0001743881 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 BUSINESS PHONE: (650) 391-9740 MAIL ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 FORMER COMPANY: FORMER CONFORMED NAME: BridgeBio Pharma LLC DATE OF NAME CHANGE: 20180618 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-01-02 0 0001743881 BridgeBio Pharma, Inc. BBIO 0001779990 HENDERSON MICHAEL THOMAS C/O BRIDGEBIO PHARMA, INC. 421 KIPLING STREET PALO ALTO CA 94301 0 1 0 0 See Remarks Common Stock 2020-01-02 4 S 0 1500 32.6894 D 180737 D Common Stock 2020-01-02 4 S 0 2002 33.6118 D 178735 D Common Stock 2020-01-02 4 S 0 115 34.4483 D 178620 D Common Stock 2020-01-03 4 S 0 332 32.2789 D 178288 D Common Stock 2020-01-03 4 S 0 26 33.0004 D 178262 D This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. Represents the weighted average sale price of the shares sold from $32.15 to $33.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 4, 5, 6 and 7. Includes 1,470 shares acquired by the Reporting Person on December 31, 2019 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Represents the weighted average sale price of the shares sold from $33.16 to $34.15 per share. Represents the weighted average sale price of the shares sold from $34.34 to $35.17 per share. Represents the weighted average sale price of the shares sold from $31.87 to $32.86 per share. Represents the weighted average sale price of the shares sold from $32.91 to $33.14 per share. Senior Vice President, Asset Acquisition, Strategy and Operations /s/ Brian Stephenson, Attorney-in-Fact 2020-01-06